Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16839732 | 0.97 | OPRL1 (0.41) | OPRL1TRPV3MTORSSTR3LSS | |
| SCHEMBL16839822 | 0.89 | MMP2 (0.41) | OPRL1MTORLSSMAPK14PPARA | |
| SCHEMBL16839812 | 0.88 | PPARG (0.43) | TRPV3SSTR3 | |
| SCHEMBL18025455 | 0.86 | CD274 (0.39) | OPRL1TRPV3MTORSSTR3PPARA | |
| SCHEMBL3740630 | 0.85 | CA12 (0.45) | SSTR3 | |
| SCHEMBL16839832 | 0.84 | PPARG (0.46) | MTORLSS | |
| SCHEMBL16839780 | 0.82 | CYP3A4 (0.47) | PPARA | |
| SCHEMBL16839820 | 0.81 | P2RX7 (0.43) | — | |
| SCHEMBL16839850 | 0.81 | HPGD (0.42) | — | |
| SCHEMBL16839709 | 0.81 | SMN1; SMN2 (0.42) | SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | OPRL1 3165/4885TRPV3 3976/4885MTOR 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.